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Abstract 
‘251-Labeled prothymosin a (ProTa) was used to study the presence and characteristics of receptors for ProTa on human peripheral blood 
mononuclear cells (PBMC). The kinetics of ‘251-ProTa binding to PBMC was fast at 37”C, whilst it required 50 min to reach equilibrium at 4°C 
and room temperature. Analysis of steady state binding data by the method of Scatchard and by unlabeled ProTa competition experiments identified 
two binding sites with an apparent equilibrium dissociation constant of 216321 pM for the high-affinity receptor and of 11.421.1 nM for the 
low-affinity one; the sites per cell ranged from 1,479 to 1,519 and from 47,547 to 56,169, respectively. The kinetically derived equilibrium dissociation 
constant agreed with these data and showed no interaction between receptors. 
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1. Introduction 
Prothymosin a (ProTa) is a highly acidic polypeptide 
first isolated from rat thymus by Haritos et al. [l] as a 
putative precursor of thymosin a1 (Ta,). Calf thymus 
ProTa contains 109 amino acid residues and is identical 
to human ProTa except for having glutamic acid instead 
of aspartic acid at position 31 and alanine instead of 
serine at position 83 [2]. 
ProTa was called ‘thymic hormone’ because it was 
detected in blood serum [3], although all evidence accu- 
mulated during the past years indicates that ProTa plays 
an intracellular role linked with cell proliferation [4,5] 
and there is no agreement on the question of whether it 
serves as a precursor for secreted thymic peptides (Ta, 
and others) or is itself secreted [6-91. However, ProTa 
presents immunopharmacological properties. In in vivo 
experiments it was shown to protect mice infected with 
Candida albicans and to increase the production and 
release of migration inhibitory factors by mononuclear 
cells [lo]. ProTa has also been shown to be active in vitro 
by enhancing T lymphocyte proliferative responses in 
patients with autoimmune deseases [11,12], and in- 
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creased the PHA-induced proliferation of fresh human 
peripheral blood mononuclear cells (PBMC) [ 131 by en- 
hancing the IL-2R expression in these cells. Recently, it 
was demonstrated that ProTa increases HLA-DR sur- 
face Ag expression and mRNA accumulation in cultured 
human monocytes, U937 human monocytic cell line and 
human B cell lines [14]. Moreover, ProTa enhances 
human Natural Killer cell activity [15], restores de- 
pressed cytotoxicity in patients with cancer [ 161 and syn- 
ergizes with IL-2 in the induction of Lymphokine Acti- 
vated Killer cells [17]. 
We report herein the availability of ‘251-ProTa with 
high specific activity and high biological activity that 
allowed us to characterize the presence, number, affinity 
and kinetics of two receptors with high and low affinities 
for bovine ProTa in human peripheral blood mononu- 
clear cells. 
2. Materials and methods 
2.1. Labeling of ProTa with “‘I 
Prothymosin a isolated from calf thymus and tested for purity by 
amino acid analysis and high voltage electrophoresis was purchased 
from Peninsula Laboratories (England) and was endotoxin free accord- 
ing to the Limulus assay. 5 pg of ProTa in 10 ~1 of borate buffer 
were reacted with 0.3 pg of Sulpho-SHPP (Sulphosuccinimidyl- 
(hidroxyphenyl)propionate) supplied by Pierce Europe (Holland) for at 
least 12 h at 4°C as described [18]. Iodination of esteriticated lysines 
proceeded by Iodobeads (Pierce), a modification of the T chloramine 
method first described by Markwell [19]. We add our dissolved protein 
(10 pg) per mCi) to the reaction vial with the Na’*‘I solution (Du Pont 
NEN, Germany), according to the manufacturers instructions. The 
incorporation was always between 21 and 36% (mean 27%) after elim- 
inating the free iodinated radicals, reaching specific activities in the 
range from 21 to 36 pCi&g (between 2 and 3 x lOI cpm/mmol). 
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2.2. SDS-Polyacrylamide gel electrophoresis (SDS-PAGE) 
Radioiodinated and purified ProTa, were analyzed on 15% gels by 
SDS-PAGE according with the method of Laemmli [20] with or without 
5% 2-mercaptoethanol. The analysis by autoradiography revealed a 
major band with an M, of around 13 kDa and secondary weaker bands 
of around 3638 kDa and 60-65 kDa (Fig. 1), both in reducing and 
non-reducing conditions. This data agrees with the experimental data 
for gel filtration which we [21] and others [22] have obtained, deducing 
that ProTa presents a strong aggregating tendency. 
2.3. ProTa bioassays 
The biological activity of ?-ProTa was checked in two different 
ways: 
(1) In our previous work we had optimized an ELISA assay [ 181 consid- 
ering the presence of specific anti-ProTa antibodies in sera from sys- 
temic lupus erythematosus (SLE) patients. In order to check the anti- 
genie recognition of ‘*‘I-ProTa, 200 ng of labeled or unlabeled protein 
were added per well to polyvinyl titulation plates, and the ELISA assay 
developped. The antigenic recognition of the autoantibodies never de- 
creased below 15% (comparing the absorbances). 
(2) ProTa increases the expression of the p70 chain of IL-2R [ 151 in YT 
cells (an NK-like cell line established from a patient with acute lym- 
phoblasic lymphoma and thymoma [23]) and for this reason we com- 
pared the activity of ‘Z51-ProTa to that of unlabeled protein. 5 x IO6 YT 
cells were resuspended in culture medium as already described in the 
presence of labeled or unlabeled protein for 6 h. Fluorescence analysis 
was performed as described [15], and the results analyzed in a Coulter 
EPICS V flow cytometer using FACS and Research and Consort 30 
software. The percentage of ProTa that remained biologically active in 
this assay after iodination was between 75 and 100%. 
2.4. ProTa receptor binding assay 
PBMC (95 f 5% lymphocytes and monocytes) obtained from hepar- 
inized blood of normal adult volunteers collected by Ficoll-Paque gra- 
dient centrifugation as described [15] were resuspended in binding 
buffer (RPM1 1640, 5% FCS and 25 mM HEPES, pH 7.4) at a cellular 
density of 10 x lo6 cells/ml and incubated with various concentrations 
of “‘1-ProTa from 70 pM to 28 nM at 4°C or room temperature for 
the designated times. In the competitive binding experiments the cells 
were incubated with a constant amount of radiopeptide (70 PM) in the 
presence of 0 to 20 nM of ProTa at room temperature for the desig- 
nated times. Cell-bound radioactivity was separated from free radioac- 
tivity by centrifugation of the assay mixture through cold FCS for 90 
s at 10,000 x g and the tip containing the cell pellet excised. Both 
radioactivities were measured in a gamma counter (Gamma counting 
system, Kontron). Nonspecific binding was determined by inclusion of 
at least 50-100 times more unlabeled protein in each assay. The incuba- 
tions were always carried out on two duplicated samples. Receptor 
binding data were analyzed by using the nonlinear egression programs 
EBDA, Ligand and Kinetic [24] as adapted by McPherson [25] for PCs 
(from Elsevier BIOSOFT, Cambridge, U.K.). 
3. Results and discussion 
1251-ProTa: recognized binding molecules or sites in the 
surface of the lymphocytes depending on the time and 
temperature, and it did it in a saturable and reversible 
manner. 
3.1. Specljicity of radiolabeled ProTa binding to PBMC 
The specificity of ‘251-ProTa binding to PBMC was 
established by performing binding assays in the presence 
of the proteins with the highest competition potential 
regarding structure and biological function. Thus, unla- 
beled ProTa inhibited the recognition of radiolabeled 
ProTa (as we will later explain in the competition tests) 
at IC,, concentration of 1.2 nM; also, sera from patients 
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Fig. 1. Analysis of ‘251-ProTa in SDS-PAGE. The labeled and purified 
ProTa was treated using a sample buffer with (channel 2) and without 
(channel 1) 5% 2-mercaptoethanol and was run in gels of 15% as 
described in section 2. The molecular weight indicated in the margin of 
the figure was estimated from protein standards (BioRad) that were 
electrophorized in parallel channels. 
of SLE containing autoantibodies against ProTa [ 181 did 
it at 1:20 dilution. However, the presence of Tal at con- 
centrations of up to 1 PM and cytokines IL-2 at concen- 
trations of up to 200 nM, IFNy and IFNa at concentra- 
tions of up to 250 nM, IL-lj? at concentrations of up to 
40 nM and PHA and BSA control peptides at concentra- 
tions of up to 250 nM, did not block this binding signif- 
icantly (data not shown). 
3.2. Kinetics of radiolabeled ProTa binding to PBMC 
‘25 The binding of I-ProTa to the cellular surface was 
fast at both 4°C (data not shown) and room temperature 
(Fig. 2), reaching equilibrium after around 60 min. At 
37°C the binding was initially faster and equilibrium was 
reached after 10 min, but the maximum binding seen at 
4°C or room temperature was not achieved (data not 
shown). This lower level of binding can be related to the 
internalization and degredation of the ligand and also to 
its faster dissociation. The binding dependence of tem- 
perature is also very frequent in many receptors of 
growth factors [26]. 
The association kinetics for the binding of ‘251-ProTa 
to these cells at room temperature (see Fig. 2A) were 
determined at three concentrations: 2, 4 and 8 nM. As 
the concentrations of the free ligand did not significantly 
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Fig. 2. Kinetics of (A) Association of 2 CI), 4 (0), and 8 (0) nM. (B) 
Dissociation of ‘251-ProTo to PBMC at room temperature. 12.5 x IO6 
cells/ml were incubated with the radiopeptide for 1 h. (A) At the indi- 
cated times samples were harvested and the binding assays were per- 
formed as described in section 2; the non-specific binding was measured 
in the presence of 100 times more unlabeled ProTa and is not shown 
in the graphs. (B) After this time the cells were washed and separated 
into two groups, one that was resuspended in binding buffer (0) and 
another in binding buffer containing 500 nM of unlabeled ProTa (0); 
the cells were kept at room temperature and at the times indicated, 
samples needed for the binding assays were collected. The continuous 
curves passing through the data, expressed as dpm (decompositions per 
minute) vs. time, are calculated by means of the program Kinetic [25] 
with a two-site model. 
decrease (more than 5%) as a result of their binding to 
the cells, we carried out the experiments under pseudo 
first order conditions. We have analyzed the curves of 
Fig. 2 by means of the Kinetic [25] computer program 
for the determination of actual association constants (KJ 
or the dissociation constants. The data from Fig. 2A 
were significantly consistent for a two-receptor model in 
PBMC. The observed association constants (Kobs) ac- 
cording to the program for each concentration were 
0.216, 0.169 and 0.371 min-’ for the high-affinity recep- 
tor and 0.039,0.021 and 0.032 min-’ for the low-affinity 
receptor. Fig. 2B shows the dissociation of ‘251-ProTa t 
room temperature that also displays two stages, one 
faster than the other. Although the one receptor model 
is accepted, the two receptor model is more appropriate, 
but not significantly so. It can be appreciated that with- 
out unlabeled ProTa competing (where only a fraction 
of the receptors are thus occupied) the dissociation is 
slower than when ProTa is present in excess, in which 
case most of the receptors are occupied; the average 
binding half-life times were 42 min in the absence of 
unlabeled protein and 27 min when ProTcl was present. 
The average of the values of the dissociation constants 
(K-J provided by the program were 4.8 & 3.1 and 
4.9 f 2.1 x 10e2 min-‘, respectively, for the fast compo- 
nent and 2.3 f 1.2 and 3.3 & 0.1 x 10e3 min-‘, respec- 
tively, for the slow component of the curve. Comparing 
the constants in the presence of excess ProTa we can 
conclude that there is no specific sensitivity to the occu- 
pation of the receptors that may indicate the presence of 
cooperativity between them. 
We determined the actual association constants at 
room temperature from the observed association data, 
the ligand concentration and the dissociation constants 
as described [25]. Thus, the values for the real association 
constants of “‘1-ProTa were 5.1 f 2.8 and 
0.9 k 0.78 x lo-’ pM-‘.min-‘, respectively, in the high- 
and low-affinity receptors. Kinetic Kns that were calcu- 
lated as a ratio of dissociation and association kinetic 
rate constants for 4 individuals ranged from 167 to 750 
pM and 778 pM to 1.6 nM, respectively, for the high- 
affinity and the low-affinity receptor in PBMC. For both 
types of receptors the kinetic data indicate that the asso- 
ciation values are of the order of 10 times higher than 
those corresponding to dissociation which causes the rel- 
atively high Kns when compared to the concentration of 
ProTa at which their biological activities are maximized 
(around 14 nM) [15]. This combination of fast associa- 
tion and slow dissociation values at temperatures be- 
tween 4°C and room temperature is also frequent in 
many cytokine receptors [27]. 
3.3. Equilibrium binding analysis of radiolabeled ProTa 
binding to PBMC 
The steady state binding of 1251-ProTa to PBMC at 
room temperature was saturable as shown in Fig. 3. 
Transformation of the data by the method of Scatchard 
[24] resulted in two straight lines, revealing two types of 
binding sites in these cells with different affinity for la- 
beled protein, with an apparent KD of 64 pM and 1,166 
sites per cell for the high-affinity receptor and 1.48 nM 
and 53,002 sites per cell for the low-affinity one. The K,s 
and number of sites per cell for 7 individuals ranged 
between 38-208 pM and between 883-1,479 sites for the 
high-affinity site, and from 12.418.2 nM and 47,547- 
58,457 sites, respectively, for the low-affinity one. 
The affinity of ProTa for its receptor on PBMC can 
also be estimated from unlabeled ProTa competition ex- 
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Fig. 3. Equilibrium condition binding of ‘251-ProTa to PBMC at room temperature. Cells, 12.5 x lo6 PBMC/ml were incubated for 1 h with increasing 
concentrations of “‘1-ProTa in the presence or absence of 1 pg/ml of ProTa. Specific and total binding were calculated as described in section 2. 
The plot shows analysis of the specific binding data (which express the percentage of bound protein with respect to free protein for each protein 
concentration, expressed as molarity) according to the method of Scatchard as determined by Ligand [24,25] with a two-site model. 
periments. In 4 experiments at room temperature, by between 2 16321 pM and 11421.1 nM for each one of 
adding increasing amounts of the unlabeled ligand we the sites. It also identified between 1,519-2,257, and be- 
obtained an inhibition of the ‘251-ProTa binding. The tween 42,822-56,169 sites per cell (Fig. 4), which is also 
computer analysis of this data provided K, which ranged in good agreement with the K,s and sites per cell gener- 
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Fig. 4. Competitive binding of ‘251-ProTa to PBMC by unlabeled ProTa. The cells, 12.5 x lo6 PBMC/ml, are incubated with 4 nM of radiopeptide 
in the presence of 0 to 100 times more unlabeled protein for 1 h at room temperature. The radioactivity of the cell is determined as described in section 
2. The data represents the specific binding of ‘*‘I-ProTa and is expressed as the amount of labeled protein that is bound (%) in the presence of 
competing ProTa (Log[C] expressed in M). The continuous curve passing through the data was calculated by the Ligand program [24] for the 
high-affinity site using the K,, value of 64 pM. The representation for the low-affinity site on PBMC (data not shown) assumed a K,, of 1.48 nM. 
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ated by steady state binding at room temperature and 
provides additional evidence that “%ProTa interacts 
with the receptor in a fashion comparable to unlabeled 
ProTa. 
these findings might prove useful in future therapeutic 
interventions. 
The slightly higher KD measured by the method of 
Scatchard vs. the measurement of KD by kinetic-binding 
experiments may reflect the difficulty in establishing 
equilibrium binding for such a large number of recep- 
tors. In addition, the K,s calculated by kinetic or equilib- 
rium analysis were studied in different cellular prepara- 
tions which also cause a relatively large variation in the 
ranges of their values; so if we compose intermediate 
values, for the high affinity receptor the K,,s would fall 
between 167 and 321 pM, and, for the low-affinity one 
between 1.6 and 11 nM (Table 1). The composite value 
for the KD of PBMC agrees very well with the amount 
of ProTa required for its maximum bioactivity (14 nM), 
showing that the occupation of almost all the receptors 
is necessary in order to achieve it. 
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